A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

The agency’s program will be open to pharmaceutical facilities that align with “national priorities.” Elsewhere, a self-administered lupus drug was turned back and MeiraGTx picked up another gene ...

CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to ...

The drug, which has suffered multiple setbacks over the years, could finally reach the market as a treatment for a form of Gaucher disease.

Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for ...

Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because ...

The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of ...

A massive overhaul of staffing and review processes have left the agency appearing heavily driven by the Trump administration ...

The deal, which involves up to eight “next-generation” weight loss medications and could be worth more than $18 billion, ranks as the largest licensing pact of its kind since the start of 2025, ...

A spike in M&A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce ...

On a conference call, executives cited “confusion” and declining vaccination rates in the U.S. while discussing a quarterly sales decline and anticipated slower growth in 2026.

AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in ...